Loading company…
NB Health Laboratory, based in Sapporo, Japan, develops antibody drugs using its MoGRAA Discovery Engine for GPCR targets.
Founded in 2006 in Sapporo, Japan, NB Health Laboratory Co. Ltd., also called NBHL, discovers and produces functional antibodies that target G protein-coupled receptors. Its MoGRAA Discovery Engine supports drug candidates for pharmaceutical companies, academic institutions and biotech firms, mainly in North America and Asia. Revenue comes from service agreements, licensing and milestone payments. In April 2022 the company raised JPY 83 million in Series C funding from Healthcare Innovation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in